The CYDY stock forecast draws on peer comparisons, noting median multiples in the micro-cap biotech space have compressed 12% year-over-year, impacting valuation models. REE Automotive Ltd. (REE) : Free Stock Analysis Report CytoDyn (OTCQB: CYDY) has revealed promising new data about leronlimab's mechanism of action in treating solid tumors. The company's analysis of metastatic Triple-Negative Breast Cancer (mTNBC) trials showed that 88% (15/17) of patients receiving weekly doses of 525mg or higher experienced significant increases in PD-L1 expression on circulating tumor cells within 30-90 days. CYDY stock forecast incorporates macro trends in biotech funding, with sector ETFs rebounding 3.8% this week, possibly lifting small-cap names if momentum continues.